drugset / Trial / NCT04126811
Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To observe the efficacy of apatinib combined with AI regimen chemotherapy compared with AI regimen chemotherapy and single-agent apatinib in patients with unresectable soft tissue sarcoma. The main observations were progression-free survival (PFS) and progression-free control rate (PFR), followed by objective response rates (ORR, CR+PR), disease control rate (DCR, CR+PR+SD), and overall survival ( OS). To observe the safety of apatinib combined with AI chemotherapy.
Timeline
- Start
- 2019-06-01
- Primary completion
- 2019-12-31
- Completion
- 2020-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ifosfamide | Small molecule | 2000 mg/m2 | Intravenous |
| Comparator | Pirarubicin | Small molecule | 75 mg/m2 | Intravenous |
| Comparator | Rivoceranib | Small molecule | 500 mg | Oral |